The Trajectory of Blood Pressure During Pregnancy in Assisted Reproductive Females

NCT06426732 | Recruiting

• 1 other identifier: 2022-919
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

The incidence of gestational hypertension and preeclampsia in the assisted reproductive technology population during pregnancy was significantly higher than that in the general normal pregnancy population. The use of assisted reproductive technology in this population due to infertility is often accompanied by many hypertension-related factors. We established a prospective cohort study based on assisted reproductive technology pregnancy population and natural pregnancy population. Through continuous monitoring of blood pressure changes and other risk factors during pregnancy in the two groups, we explored the trajectory trend and inflection point of assisted reproductive technology pregnancy population blood pressure during pregnancy. Through factor analysis, the risk factors of elevated blood pressure during pregnancy can be clearly identified, so as to carry out early intervention and strengthen the control of risk factors of elevated blood pressure in assisted reproductive technology population, in order to expect benign maternal and infant outcomes.

Conditions

Blood Pressure

Outcome Measures

Primary Outcomes (1)

• The Trajectory of Blood Pressure During Pregnancy in Assisted Reproductive Females

  The Trajectory of Blood Pressure During Pregnancy in Assisted Reproductive Females

  from pregnancy to delivery

Study Arms (2)

Natural pregnancy group

Assisted Reproductive Technology Group

Eligibility Criteria

• Age: 20 Years - 45 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

collect sixty patients in each group

You may qualify if:

• Exposure group:
• Mother: Seen in the obstetrics department of our hospital and meet the following conditions at the same time:
• Complete at least one cycle of IVF or ICSI, PGD or IVM treatment (including natural cycles);
• Clinical pregnancy was obtained after treatment. Offspring: Offspring born after in vitro fertilization-embryo transfer technique.
• Non-exposed group:
• Mother: A mother who conceived naturally. Offspring: 1) Offspring born by natural pregnancy. 2) Offspring born from natural pregnancy of exposed mothers.

You may not qualify if:

• Unwilling to participate in this research;
• Unable to participate in this study due to special reasons, such as death, immigration, loss to follow-up;
• Hereditary diseases, mental diseases, malignant tumors, pre-pregnancy hypertension, uterine malformations and other reproductive organ malformations;
• Pregnant women who voluntarily terminate pregnancy due to non-preeclampsia factors;

Sponsors & Collaborators

• The Second Hospital of Shandong University: lead

Study Sites (1)

Cui linlin

Jinan, China

RECRUITING

Central Study Contacts

Wenting Wang, M.D. Ph.D.

CONTACT

+86 17660082326; 13188936075@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: May 18, 2024
• First Posted: May 23, 2024
• Study Start: November 1, 2022
• Primary Completion: December 31, 2024
• Study Completion: June 30, 2025
• Last Updated: May 23, 2024

Record last verified: 2024-05

Locations

CN (1)